Cure My Disease

Don't miss your cure!

 Log in / Sign up

New website aims to close cancer care gap for black patients

NCT ID NCT05034289

Knowledge-focused Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to see if the website was acceptable and helpful in empowering patients to make informed decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

81 people

The number who actually took part.

Started

Jul 2021

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Patient Key Informant: * Age 18 and older * Self-identify as Black/African American * Diagnosed with solid tumor * Able to read and speak English fluently * Able to provide informed consent * Able to complete 1 survey and an in-depth interview Relative Key Informant: * Age 18 and older * Spouse, blood relative, or caregiver of a cancer patient who identifies as Black/African American * Able to read and speak English fluently * Able to provide informed consent * Able to complete 1 survey and an in-depth interview Provider Key Informant: * Age 18 and older * Physician, nurse, social worker, patient navigator, or financial counselor * Work in oncology setting * Able to read and speak English fluently * Able to provide informed consent * Able to complete 1 survey and an in-depth interview Pilot Tester: * Age 18 and older * Self-identify as Black/African American * Able to read and speak English fluently * Able to provide informed consent * Newly diagnosed with solid tumor cancer (Stage I-IV) * Have not yet consulted with an oncologist regarding treatment * Able to complete 2 surveys and an in-depth interview Exclusion Criteria Key informants will be excluded from the study if they do not meet the inclusion criteria. Pilot testers will be excluded from the study if they previously participated as key informants and do not meet inclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical trials are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical trials Immunotherapy

Contacts and locations

Locations

  • The Rutgers Cancer Institute

    New Brunswick, New Jersey, 08901, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.